Lopinavir for COVID-19

Home COVID-19 treatment studies COVID-19 treatment studies COVID-19 studies Select treatmentSelect treatmentTreatmentsTreatments

Acetaminophen	Meta
Aspirin	Meta
Ibuprofen	Meta
Indomethacin	Meta
Close

Diet	Meta
Exercise	Meta
Sleep	Meta
Sun	Meta
Close

Antiandrogens..

All	Meta
Proxalutamide	Meta
Spironolactone	Meta
Close

Bamlaniv../e..	Meta
Bebtelovimab	Meta
Casirivimab/i..	Meta
Sotrovimab	Meta
Tixagev../c..	Meta
Close

Iota-carragee..

Vitamin A	Meta
Vitamin B9	Meta
Vitamin C	Meta
Vitamin D	Meta
Close

Other Treatments

Global Adoption

Lopinavir for COVID-19

Home

Global AdoptionAdoption

Submit FeedbackFeedback

Lopinavir has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.

lopinavir Submit Updates

Oliver et al., Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus, Therapeutic Advances in Vaccines and Immunotherapy, doi:10.1177/25151355221144845

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Nayak et al., Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease, Journal of Personalized Medicine, doi:10.3390/jpm13040664

Oner et al., Investigation of antiviral substances in Covid 19 by Molecular Docking: In Silico Study, African Health Sciences, doi:10.4314/ahs.v23i1.4

Kumar et al., COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery, Genes & Diseases, doi:10.1016/j.gendis.2022.12.019

Astasio-Picado et al., Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2), Applied Sciences, doi:10.3390/app13074471

Khaerunnisa et al., Potential Inhibitor of COVID-19 Main Protease (M<sup>pro</sup>) From Several Medicinal Plant Compounds by Molecular Docking Study, MDPI AG, doi:10.20944/preprints202003.0226.v1

Talukdar et al., Potential Drugs for COVID -19 Treatment Management With Their Contraindications and Drug- Drug Interaction, MDPI AG, doi:10.20944/preprints202105.0690.v1

Raghav et al., Potential treatments of COVID-19: Drug repurposing and therapeutic interventions, Journal of Pharmacological Sciences, doi:10.1016/j.jphs.2023.02.004

Guo et al., Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy, Briefings in Bioinformatics, doi:10.1093/bib/bbac628

Supianto et al., Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015

Zeng et al., Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning, Journal of Proteome Research, doi:10.1021/acs.jproteome.0c00316

Shah et al., In silico studies on therapeutic agents for COVID-19: Drug repurposing approach, Life Sciences, doi:10.1016/j.lfs.2020.117652

Mousavi et al., Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282

Zhong et al., Recent advances in small-molecular therapeutics for COVID-19, Precision Clinical Medicine, doi:10.1093/pcmedi/pbac024

Mavlankar et al., Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study, F1000Research, doi:10.12688/f1000research.109586.1

Arshad et al., Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1909

Loucera et al., Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk., medRxiv, doi:10.1101/2022.08.14.22278751

Jamalipour Soufi et al., Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736

Rani et al., Modern drug discovery applications for the identification of novel candidates for COVID-19 infections, Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.104125

Davarpanah et al., Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study, medRxiv, doi:10.1101/2022.01.21.22269322

Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870

Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit